ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0608 • ACR Convergence 2020

    Patient and Parent Perspectives in a Academic Pediatric Rheumatology Transition Clinic

    Rebecca Overbury1, Tracy Frech2, John Bohnsack3, CJ Inman1, Sara Stern1, Karen James1, Erin Treemarcki4 and Aimee Hersh4, 1University of Utah and Primary Children's Hospital, Salt Lake City, UT, 2University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, 3University of Utah and Primary Children's Hospital, Cincinnati, OH, 4University of Utah and Primary Children's Hospital, Salt Lake City

    Background/Purpose: In November 2018 we initiated a transition clinic called ACCORD (Adult Center for Childhood Onset Rheumatic Disease). Our unique structure integrates an adult rheumatologist…
  • Abstract Number: 0622 • ACR Convergence 2020

    Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports

    Konstantinos Parperis1, Loukas Kakoullis2, Eleni Papachristodoulou3 and George Panos3, 1University of Arizona College of Medicine Phoenix and University of Cyprus Medical School, Phoenix, 2University of Patras School of Health Sciences, Patras, Akhaia, Greece, 3University of Cyprus Medical School, Nicosia, Nicosia, Cyprus

    Background/Purpose: Anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) has been implicated in the pathogenesis of microscopic polyangiitis (MPA) and an MPO-ANCA associated glomerulonephritis; both conditions are…
  • Abstract Number: 0621 • ACR Convergence 2020

    Effectiveness of Screening in Patients with Rheumatic Disease Before Commencing Biologic Therapy and Risk of Active Tuberculosis

    Sultana Abdulaziz1, Suzan Attar2, Wael Bajhammoh3, Eman Alsindi3, Eman Bakhashwain4 and Doaa Ayish5, 1King Fahd Hospital, Jeddah, Saudi Arabia, 2King Abdulaziz University, Jeddah, Saudi Arabia, 3King Fahad Hospital, Jeddah, Saudi Arabia, 4East Jeddah Hospital, Jeddah, Saudi Arabia, 5Prince Mohammed Bin Nasser Hospital, Gizan, Saudi Arabia

    Background/Purpose: Treatment with biologic therapy has been associated with a high risk of reactivation of latent tuberculosis (TB ). Preventive strategies for tuberculosis remain a…
  • Abstract Number: 0627 • ACR Convergence 2020

    Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series

    Timothy Buckey1, Mali Jurkowski1, Kevin Lu2, Roberto Caricchio2 and Aruni Jayatilleke2, 1Temple University, Philadelphia, PA, 2Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    Background/Purpose: People with rheumatic diseases may be at high risk for poor outcomes related to COVID-19; on the other hand, immunomodulatory medications are used as…
  • Abstract Number: 0626 • ACR Convergence 2020

    Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients

    Alisa Mueller1, Tomoyoshi Tamura2, Julia Jezmir3, Erin Penn1, Gregory Keras4, Anthony Massaro5 and Edy Kim5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 3Brigham and Women’s Hospital, Department of Medicine, Boston, MA, 4Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA

    Background/Purpose: During the course of hospitalization, it is often unclear which COVID-19 patients will progress from non-critical to critical illness. Timely identification of these patients…
  • Abstract Number: 0632 • ACR Convergence 2020

    Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases

    Valeria Valerio1, Mariana Useche1, Erin Field2, Mianbo Wang3, Elizabeth M. Hazel4, Brian Ward5 and Ines Colmegna1, 1The Research Institute of the McGill University Health Centre, Montreal, Canada, 2The Research Institute of the MUHC, Montreal, Canada, 3Lady Davis institute for Medical Research, Montreal, QC, Canada, 4McGill University Health Centre, Montreal, Canada, 5The Research Institute of the McGill University Health Centre, Monreal, QC, Canada

    Background/Purpose: A vaccination coverage goal of 80% with the seasonal influenza vaccine was established to protect people at high-risk for influenza-related complications or hospitalizations (e.g.…
  • Abstract Number: 0634 • ACR Convergence 2020

    Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic

    Julia Harris1, Maria Ibarra2, Michael Holland2, Kelly Jensen3, Emily Fox2, Jordan Jones2, Leslie Favier4, Ashley Sherman2, Chelsey Smith5 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO, 3Children's Mercy Kansas City, Kansas City, 4Children's Mercy Kansas City, Leawood, KS, 5Children's Mercy Kansas City, Holden, MO

    Background/Purpose: Many pediatric rheumatology patients are at increased risk of influenza due to immunosuppressive medication use.  Annual influenza vaccination is recommended for all children by…
  • Abstract Number: 0629 • ACR Convergence 2020

    COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study

    Jesús Loarce-Martos1, Antía García-Fernández1, Fernando López-Gutiérrez1, Veronica Garcia2, Laura Calvo-Sanz1, Ivan Del Bosque-Granero2, Cristina Pijoan-Moratalla1, Lourdes Villalobos-Sánchez3, Boris Blanco-Cáceres1, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMID) have a higher risk of infections related to their disease, comorbidities or immunosuppressive treatments, but recent studies addressing…
  • Abstract Number: 0624 • ACR Convergence 2020

    Association of Regional Body Composition and Physical Function Using the Short Physical Performance Battery Among Peruvian Women with HIV

    Diego Cabrera1, Mijahil Pavel Cornejo Ortega2, Yvett Pinedo3, Patricia Garcia4 and Evelyn Hsieh5, 1Yale University, Universidad Peruana Cayetano Heredia, Lima, Peru, 2Hospital Nacional Arzobispo Loayza, Lima, Peru, 3Hospital Nacional Arzobispo Loayza, Lima, 4Universidad Peruana Cayetano Heredia, Lima, Peru, 5Yale University School of Medicine; West Haven VA, New Haven, CT

    Background/Purpose: The musculoskeletal (MSK) system is significantly affected by HIV and its treatment. Changes in body composition can reflect important changes in bone and MSK…
  • Abstract Number: 0637 • ACR Convergence 2020

    Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time

    Benjamin Naovarat1, Francis Williams1 and John Reveille2, 1The University of Texas McGovern Medical School, Houston, TX, 2Department of Internal Medicine, University of Texas, Houston, TX

    Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
  • Abstract Number: 0640 • ACR Convergence 2020

    Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence

    Kieran Murray1, Sean Quinn2, Matthew Turk2, Anna O'Rourke3, Eamonn Molloy1, Lorraine O'Neill4, Anne Mongey5, Ursula Fearon6 and Douglas Veale7, 1Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, 2Saint Vincent's University Hospital, Dublin 4, Ireland, 3Saint James' University Hospital, Dublin 6, Ireland, 4Saint Vincent's University Hospital, Dublin, Ireland, 5Saint Vincent's University Hospital, Co Dublin, Ireland, 6Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, 7EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland

    Background/Purpose: Covid-19 has caused >400,000 deaths. The relationship between RMDs, immunosuppressive medications and Covid-19 is unclear. This study explores Covid-19 prevalence, DMARD adherence, information sources…
  • Abstract Number: 0641 • ACR Convergence 2020

    Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?

    Antía García-Fernández1, Fernando López-Gutiérrez1, Jesús Loarce-Martos1, Ivan Del Bosque-Granero2, Laura Calvo-Sanz1, Boris Blanco-Cáceres1, Cristina Pijoan-Moratalla1, Lourdes Villalobos-Sánchez3, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid

    Background/Purpose: There are very few studies reporting COVID-19 in patients with rheumatic diseases, without clear evidence supporting more frequent or severe disease in these patients.…
  • Abstract Number: 0636 • ACR Convergence 2020

    Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic

    Cuoghi Edens1, Kichul Ko1 and Kimberly Trotter1, 1University of Chicago, Chicago, IL

    Background/Purpose: Rheumatic disease patients are counseled on the immunosuppressive aspect of their rheumatic disease treatment and their increased risk of infection.  Little is known about…
  • Abstract Number: 0644 • ACR Convergence 2020

    Characterizations of Cytokine Storm Associated with COVID19

    Ofer Perzon1, Avi Abutbul1, Sigal Sviri1 and Dror Mevorach1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: COVID-19, the name given to the clinical syndrome associated with the newly recognized virus SARS-CoV-2 has become pandemic with mortality estimated based on reports…
  • Abstract Number: 0639 • ACR Convergence 2020

    Immunological Abnormalities in a SARS-CoV-2-Cytokine Release Syndrome Rheumatology Cohort

    Patil Injean1, Sandy Lee1, Neha Chiruvolu2, Muntarin Karim3, Loomee Doo4, Deepa Ragesh Panikkath5, Donna Jose4, Micah Yu4, Anna Lafian4, Vaneet Sandhu6, Karina Torralba7, Christina Downey1, Marven Cabling8 and Mehrnaz Hojjati9, 1Loma Linda University Medical Center, Redlands, CA, 2UC Riverside School of Medicine, Riverside, CA, 3Loma Linda University Health System, Loma Linda, CA, 4Loma Linda University Medical Center, Loma Linda, CA, 5Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, 6Loma Linda University, Loma Linda, CA, 7Loma Linda University School of Medicine, Redlands, CA, 8Loma Linda University Medical Center, Loma Linda, 9Loma Linda University, Loma Linda

    Background/Purpose: Cytokine release syndrome (CRS) is a condition characterized by a sepsis-like condition and laboratory abnormalities such as high ferritin, low ESR, and low fibrinogen…
  • « Previous Page
  • 1
  • …
  • 667
  • 668
  • 669
  • 670
  • 671
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology